The ARVO/Alcon Keynote Series is supported by the ARVO Foundation through a contribution from Alcon Laboratories.
View the 2016 ARVO/Alcon Keynote Series.
ARVO/Alcon Keynote Series 2015
Sunday, May 3; 12 – 1:15pm
Ninja Innovation – Where Technology is Taking Us
Gary Shapiro, President and CEO, Consumer Electronics Association (CEA)®
Thursday, May 7; 1:55 – 3:15pm
Ebola and the Eye: A story of discovery and uncertainty
- Ian Crozier, MD
- Tim Uyeki, MD
- Jay B. Varkey, MD
- Steven Yeh, MD
- Jessica G. Shantha, MD
Moderator: William F. Mieler, MD, FARVO
ARVO/Alcon Keynote Series 2014
Professor Barry Marshall
AC Nobel Laureate
How curiosity driven research can lead to the Nobel Prize
Sunday, May 4
Jean Bennett, MD, PhD, FARVO
University of Pennsylvania
Seeing the light with retinal gene therapy: Things you wished you'd known early on your way to late stage trials
Thursday, May 8
ARVO/Alcon Keynote Series 2013
Oliver Smithies, DPhil
2007 Nobel Laureate,
of North Carolina at Chapel Hill
On Being a Scientist for 60 Years
2:45 – 4:15pm, Sunday, May 5
Roger Tsien, PhD
Cancelled due to illness
Christopher Murray, MD, DPhil
Institute for Health Metrics and Evaluation University of Washington, Seattle
Global Burden of Disease Study 2010: Key Findings and Implications for Vision Research
2 – 3:15pm, Thursday, May 9
ARVO/Alcon Keynote Session 2012
J. Craig Venter, PhD
J. Craig Venter Institute
From Reading to Writing the Genetic Code
Venter is one of the 21st century’s leading scientists. He has made numerous contributions to genomic research, including publication of the first draft human genome in 2001, first complete diploid human genome in 2007 and creation of the first self-replicating bacterial cell constructed entirely with synthetic DNA.
He is founder, chairman and president of the J. Craig Venter Institute, a nonprofit organization with approximately 300 scientists and staff dedicated to human, microbial, plant, synthetic and environmental genomic research, and the exploration of social and ethical issues in genomics. He is also founder and CEO of Synthetic Genomics Inc., a privately held company developing and applying genomic-driven commercial solutions to markets including biofuels, biochemicals and new bio-based food products.
ARVO/Alcon Keynote Session 2011
Roderick R. McInnes, MD, PhD
Genomic medicine and the future of eye research
McInnes is the director of the Lady Davis Institute of the Jewish General Hospital, the Canada Research Chair in Neurogenetics, and professor of genetics and of biochemistry at McGill University. He is also Chair in physiology (genetics and ophthalmology) at the University of Manchester, UK.
He has made important contributions to the understanding of the molecular basis of retinal and eye development, and to the identification of genes and processes associated with inherited retinal degenerations.
ARVO/Alcon Keynote Session 2010
Robert S. Langer, ScD
David H. Koch Institute
The Future of Drug Delivery and Regenerative Medicine in Ophthalmology Chemical engineer
Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology. The Langer Lab at MIT is the largest biomedical engineering lab in the world, maintaining over $6 million in annual grants. Langer is considered a pioneer of many new technologies, including transdermal delivery systems, which allow the administration of drugs or extraction of analytes from the body through the skin. He and the researchers in his lab have also made advances in tissue engineering, such as the creation of vascularized engineered muscle tissue and engineered blood vessels. Langer has been elected to the Institute of Medicine of the National Academy of Sciences, the National Academy of Engineering and the National Academy of Sciences.
ARVO/Alcon Keynote Session 2009
Hugh Taylor, MD
University of Melbourne
Washington to Ouagadougou: Who Deserves to See?
Taylor has worked among the world’s most disadvantaged populations during his career, which has been devoted to research on strategies for the prevention and control of blinding diseases, particularly trachoma. He has successfully combined laboratory and clinical research, extensive field work, consulting to the World Health Organization and other agencies, and a respected record of publication. Made a Companion of the Order of Australia in 2001, Taylor was also the recipient of ARVO’s 2002 Weisenfeld Award.
ARVO/Alcon Keynote Session 2008
Kurzweil Technologies, Inc.
The Law of Accelerating Returns
Kurzweil is a leader in groundbreaking technologies like the CCD flat-bed scanner and omni-font optical character recognition-was the featured speaker at the 2008 ARVO/Alcon Keynote Session.
Kurzweil pioneered the print-to-speech reading machine for the blind and the text-to-speech synthesizer. His latest book, The Singularity is Near, is a New York Times bestseller. Mr. Kurzweil received the MIT-Lemelson Prize, the world’s largest award for innovation, as well as a 1999 National Medal of Technology from President Clinton.